Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Neratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 19/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | MAP3K13 | O43283 | 1/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neratinib SCHEMBL571763 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL29376313 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL15163655 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL29394766 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL29801657 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL15163654 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL2385159 | 0.97 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL22408867 | 0.97 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL2180998 | 0.97 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL2385190 | 0.97 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10258 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746970-A1 | EGFR ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING UNWANTED MIGRATION, PROLIFERATION, AND/OR METAPLASIA OF RETINAL PIGMENT EPITHELIUM (RPE) CELLS | Jonas, Jost B. (DE) | 2026-05-27 | — | — | EP | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139324-A1 | CLASSIFICATION OF BREAST TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | GUARDANT HEALTH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139325-A1 | CLASSIFICATION OF COLORECTAL TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | GUARDANT HEALTH INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4744054-A1 | CLASSIFICATION OF COLORECTAL TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | Guardant Health, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4744051-A1 | CLASSIFICATION OF BREAST TUMORS USING DNA METHYLATION FROM LIQUID BIOPSY | Guardant Health, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-1670473-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2006-06-21 | — | — | EP | claimed |
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | WYETH (US) | 2006-06-15 | — | — | US | claimed |
| WO-2006044453-A1 | ANALOGS OF 17-HYDROXYWORTMANNIN AS PI3K INHIBITORS | WYETH (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006042100-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH (US) | 2006-04-20 | — | — | WO | claimed |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | claimed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | claimed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | claimed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | claimed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | claimed |